Compare · ABSI vs PRAH
ABSI vs PRAH
Side-by-side comparison of Absci Corporation (ABSI) and PRA Health Sciences, Inc. (PRAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and PRAH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI carries a market cap of $1.65B.
- ABSI has hit the wire 6 times in the past 4 weeks while PRAH has been quiet.
- ABSI has more recent analyst coverage (21 ratings vs 0 for PRAH).
- Company
- Absci Corporation
- PRA Health Sciences, Inc.
- Price
- $9.64+8.80%
- $165.29-1.68%
- Market cap
- $1.65B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 21
- 0
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- SEC Form 4 filed by CMO, Head of R&D Somaratne Ransi Mudalinayake
- SEC Form 3 filed by new insider Somaratne Ransi Mudalinayake
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
Latest PRAH
- Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
- SEC Form SC 13G filed by PRA Health Sciences, Inc.
- SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)
- SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Young Matthew P. returned 7,127 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Stettin Glen D. returned 1,049 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: MOMTAZEE JAMES C returned 3,521 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Dickinson Alexander George returned 5,407 units of Common Stock to the company, closing all direct ownership in the company